<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>cDNA microarray technology has been used to identify HLA-A24-restricted <z:chebi fb="0" ids="53000">epitope</z:chebi> <z:chebi fb="7" ids="16670">peptides</z:chebi> as potential targets for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> vaccination in <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> patients </plain></SENT>
<SENT sid="1" pm="."><plain>We conducted a clinical trial of two novel <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-specific <z:chebi fb="7" ids="16670">peptides</z:chebi>( RNF43, TOMM34) with UFT/LV for the treatment of <z:e sem="disease" ids="C0854750" disease_type="Neoplastic Process" abbrv="">recurrent colorectal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Among 23 patients, 21 patients had completed the protocol </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients were well tolerated with no severe toxicities </plain></SENT>
<SENT sid="4" pm="."><plain>The median survival time was 24.4 months </plain></SENT>
<SENT sid="5" pm="."><plain>Furthermore, we investigated the relationship between CTL response to both antigens and overall survival </plain></SENT>
<SENT sid="6" pm="."><plain>The best long-term survival was observed in the group with CTL responses against both antigens, followed by the group showing CTL responses against only RNF43 or TOMM34 </plain></SENT>
<SENT sid="7" pm="."><plain>The patients with no response had the lowest survival </plain></SENT>
<SENT sid="8" pm="."><plain>Based on the results, we started a randomized trial of the current protocol, as adjuvant immunochemotherapy in following curative resection of <z:e sem="disease" ids="C0677949" disease_type="Neoplastic Process" abbrv="">Stage III colorectal cancer</z:e> patients </plain></SENT>
</text></document>